Core Viewpoint - The announcement by Fuhong Hanlin (02696) indicates that its drug, Fuzhuoning® (Acalabrutinib), has been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025) under Category B, specifically for use in HR-positive, HER2-negative recurrent or metastatic breast cancer patients who have progressed after endocrine therapy [1] Group 1 - Fuzhuoning® is an innovative CDK4/6 small molecule inhibitor licensed by the company [1] - The drug was approved for marketing in China in May 2025, with its first indication being in combination with Fulvestrant for HR-positive, HER2-negative recurrent or metastatic breast cancer patients who have progressed after endocrine therapy [1] - In September 2025, Fuzhuoning® received an additional indication for use in HR-positive, HER2-negative locally advanced or metastatic breast cancer adult patients, in combination with aromatase inhibitors as initial endocrine therapy [1] Group 2 - The new National Medical Insurance Drug List will officially take effect on January 1, 2026 [1]
复宏汉霖(02696)：复妥宁(枸橼酸伏维西利胶囊)获纳入国家医保药品目录